Cargando…

Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients

Glioblastoma treatment protocol includes chemo-radiation (CRT) after maximal safe resection. However, the recommended time-gap between surgery and CRT is unclear, most trials protocol required an interval of less than 6 weeks. In the current study we evaluated the association of the time-gap between...

Descripción completa

Detalles Bibliográficos
Autores principales: Zur, Inbar, Tzuk-Shina, Tzahala, Guriel, Marina, Eran, Ayelet, Kaidar-Person, Orit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293292/
https://www.ncbi.nlm.nih.gov/pubmed/32533126
http://dx.doi.org/10.1038/s41598-020-66608-3
_version_ 1783546271996313600
author Zur, Inbar
Tzuk-Shina, Tzahala
Guriel, Marina
Eran, Ayelet
Kaidar-Person, Orit
author_facet Zur, Inbar
Tzuk-Shina, Tzahala
Guriel, Marina
Eran, Ayelet
Kaidar-Person, Orit
author_sort Zur, Inbar
collection PubMed
description Glioblastoma treatment protocol includes chemo-radiation (CRT) after maximal safe resection. However, the recommended time-gap between surgery and CRT is unclear, most trials protocol required an interval of less than 6 weeks. In the current study we evaluated the association of the time-gap between surgery and CRT to overall survival (OS) and progression free survival (PFS) in a tertiary center. After ethics committee approval, a retrospective study was conducted. Data was collected from the medical records of consecutive glioblastoma patients treated between 2005–2014. Parameters of interest included: background characteristics of patients, treatment dates and type of treatment, treatment interruptions and survival. Only patients who were diagnosed with WHO IV, underwent surgical resection (any type), and treated with postoperative CRT were included. For the analysis, patients were divided into 3 groups according to the time gap from surgery to CRT: <4 weeks, 4–6 weeks and >6 weeks. Overall survival and PFS were investigated using the Kaplan-Meier method and Cox proportional hazard model. Out of 465 patients, 204 were included. Median age was 60 years (range: 23–79 years) and 61.7% male vs. 38.3% female. There was a significant difference in OS (HR = 0.49, p-value = 0.002, 95% CI: 0.32–0.78) and PFS (HR = 0.51, p-value = 0.003, 95% CI: 0.33–0.79) in the group who was treated with CRT 6 weeks or more after surgery, compared with the other two groups tested. In our study, 6 weeks or more time-gap (median of 8 weeks) between surgery and CRT was associated with better OS and PFS among newly diagnosed glioblastoma patients. Our results are probably subjected to unaccounted biases of a retrospective study, and that CRT in this patient population is an effective therapy that overcomes the potential harm of initiating therapy later than 6 weeks. Our current approach is to initiate CRT within 6 weeks after surgery, similar to what is recommended in the literature, but the data from this study provide us with information that no major harms was done in patients who were delayed.
format Online
Article
Text
id pubmed-7293292
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72932922020-06-15 Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients Zur, Inbar Tzuk-Shina, Tzahala Guriel, Marina Eran, Ayelet Kaidar-Person, Orit Sci Rep Article Glioblastoma treatment protocol includes chemo-radiation (CRT) after maximal safe resection. However, the recommended time-gap between surgery and CRT is unclear, most trials protocol required an interval of less than 6 weeks. In the current study we evaluated the association of the time-gap between surgery and CRT to overall survival (OS) and progression free survival (PFS) in a tertiary center. After ethics committee approval, a retrospective study was conducted. Data was collected from the medical records of consecutive glioblastoma patients treated between 2005–2014. Parameters of interest included: background characteristics of patients, treatment dates and type of treatment, treatment interruptions and survival. Only patients who were diagnosed with WHO IV, underwent surgical resection (any type), and treated with postoperative CRT were included. For the analysis, patients were divided into 3 groups according to the time gap from surgery to CRT: <4 weeks, 4–6 weeks and >6 weeks. Overall survival and PFS were investigated using the Kaplan-Meier method and Cox proportional hazard model. Out of 465 patients, 204 were included. Median age was 60 years (range: 23–79 years) and 61.7% male vs. 38.3% female. There was a significant difference in OS (HR = 0.49, p-value = 0.002, 95% CI: 0.32–0.78) and PFS (HR = 0.51, p-value = 0.003, 95% CI: 0.33–0.79) in the group who was treated with CRT 6 weeks or more after surgery, compared with the other two groups tested. In our study, 6 weeks or more time-gap (median of 8 weeks) between surgery and CRT was associated with better OS and PFS among newly diagnosed glioblastoma patients. Our results are probably subjected to unaccounted biases of a retrospective study, and that CRT in this patient population is an effective therapy that overcomes the potential harm of initiating therapy later than 6 weeks. Our current approach is to initiate CRT within 6 weeks after surgery, similar to what is recommended in the literature, but the data from this study provide us with information that no major harms was done in patients who were delayed. Nature Publishing Group UK 2020-06-12 /pmc/articles/PMC7293292/ /pubmed/32533126 http://dx.doi.org/10.1038/s41598-020-66608-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zur, Inbar
Tzuk-Shina, Tzahala
Guriel, Marina
Eran, Ayelet
Kaidar-Person, Orit
Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
title Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
title_full Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
title_fullStr Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
title_full_unstemmed Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
title_short Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
title_sort survival impact of the time gap between surgery and chemo-radiotherapy in glioblastoma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293292/
https://www.ncbi.nlm.nih.gov/pubmed/32533126
http://dx.doi.org/10.1038/s41598-020-66608-3
work_keys_str_mv AT zurinbar survivalimpactofthetimegapbetweensurgeryandchemoradiotherapyinglioblastomapatients
AT tzukshinatzahala survivalimpactofthetimegapbetweensurgeryandchemoradiotherapyinglioblastomapatients
AT gurielmarina survivalimpactofthetimegapbetweensurgeryandchemoradiotherapyinglioblastomapatients
AT eranayelet survivalimpactofthetimegapbetweensurgeryandchemoradiotherapyinglioblastomapatients
AT kaidarpersonorit survivalimpactofthetimegapbetweensurgeryandchemoradiotherapyinglioblastomapatients